Anixa Biosciences Inc

Listed Company

ANIXCIK 0000715446NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Oct 31

Period

FY 2025

Revenue

—

Net Income

$-10.93M

Total Assets

$16.08M

Equity

$15.16M

Shares Out

33.53M

Op. Cash Flow

$-7.17M

Business

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. It develops CAR‑T therapeutics—via subsidiary Certainty Therapeutics—targeting the FSH receptor in solid tumors (initially ovarian cancer), and cancer vaccines including α‑lactalbumin breast cancer and AMHR2‑ED ovarian cancer vaccines, plus a discovery program for additional vaccine targets. Key business units include its Certainty subsidiary for CAR‑T therapeutics, vaccine programs in collaboration with Cleveland Clinic and NCI-supported preclinical work, and limited patent licensing activities. The company conducts clinical trials and collaborates with academic cancer centers and research institutes, primarily utilizing clinical and research channels in the United States.

Summary from filing dated 2025-01-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31
Revenue	—	—	210,000	—	512,000
Research and development expenses (including non-cash stock-based compensation expenses of $1,560 and $1,859, respectively)	5	6	5	7	6
General and administrative expenses (including non-cash stock-based compensation expenses of $2,250 and $2,923, respectively)	7	7	6	7	7
Total operating costs and expenses	12	14	11	14	14
Loss from operations	−12	−14	−11	−14	−13
Interest income	673,000	1	1	104,000	2,000
Net loss	−11	−13	−10	−14	−13
Less: Net loss attributable to noncontrolling interest	−101,000	−144,000	−119,000	−176,000	−174,000
Net loss attributable to common shareholders	−11	−13	−10	−14	−13
Basic (per share)	−0.34	−0.39	−0.32	0.45	−0.45
Diluted (per share)	−0.34	−0.39	−0.32	0.45	—
Basic (shares)	32,454	31,898	30,980	30,374	—
Diluted (shares)	32,454	31,898	30,980	30,374	29

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31
Cash and cash equivalents	1	1	915,000	12	29
Shortterm investments	14	19	23	17	7
Receivables	—	173,000	270,000	46,000	—
Prepaid expenses and other current assets	713,000	1	1	467,000	276,000
Total current assets	16	21	25	30	36
Operating lease right-of-use asset	193,000	229,000	166,000	212,000	254,000
Total assets	16	22	26	30	36
Accounts payable	165,000	525,000	206,000	265,000	136,000
Accrued expenses	2	2	2	2	1
Operating lease liability	41,000	29,000	52,000	46,000	39,000
Total current liabilities	2	3	2	2	1
Operating lease liability, non-current	163,000	203,000	123,000	175,000	220,000
Total liabilities	2	3	2	2	1
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, value	—	—	—	—	—
Common stock, par value $.01 per share; 100,000,000 shares authorized; 33,013,829 and 32,196,862 shares issued and outstanding as of October 31, 2025 and 2024, respectively	330,000	322,000	311,000	309,000	301,000
Additional paid-in capital	267	260	252	247	240
Accumulated deficit	−252	−241	−228	−218	−205
Treasury stock, 2,000 shares at cost as of October 31, 2024	—	−6,000	—	—	—
Total shareholders equity	15	20	24	29	35
Noncontrolling interest (Note 2)	−1	−1	−966,000	−847,000	−671,000
Total equity	14	19	23	28	35
Total liabilities and equity	16	22	26	30	36

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-10-31	FY 2024 2024-10-31	FY 2023 2023-10-31	FY 2022 2022-10-31	FY 2021 2021-10-31
Stock option compensation to employees and directors	4	4	4	6	8
Stock options issued to consultants	129,000	125,000	221,000	655,000	555,000
Common stock issued to consultants	—	255,000	92,000	97,000	—
Amortization of operating lease right-of-use asset	36,000	37,000	46,000	42,000	60,000
Amortization of discount on held-to-maturity securities	−143,000	—	—	—	—
Receivables	173,000	97,000	−224,000	−29,000	—
Prepaid expenses and other current assets	552,000	−23,000	−775,000	−208,000	36,000
Accounts payable	−360,000	319,000	−59,000	129,000	−96,000
Accrued expenses	−185,000	176,000	44,000	631,000	193,000
Operating lease liability	−28,000	−43,000	−46,000	—	—
Net cash used in operating activities	−7	−7	−6	−6	−5
Disbursements to acquire short-term investments	−44	−64	−44	−22	−16
Proceeds from maturities of short-term investments	49	68	39	12	13
Net cash provided by investing activities	5	4	−6	−11	−4
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $183 and $168, for the years ended October 31, 2025 and 2024, respectively	2	3	—	—	11
Proceeds from sale of common stock pursuant to employee stock purchase plan	7,000	10,000	13,000	13,000	6,000
Net (costs) proceeds from exercise of stock options	−105,000	456,000	—	—	—
Disbursements for purchases of treasury stock	—	−6,000	—	—	—
Net cash provided by financing activities	2	3	366,000	452,000	32
Net (decrease) increase in cash and cash equivalents	−27,000	356,000	−11	−17	23
Cash proceeds from interest income	686,000	1	838,000	23,000	—
Modification to operating lease right-of-use asset	—	−100,000	—	—	—
Modification to operating lease liability	—	100,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro